Reported:
Eisai Inc. v. sanofi-aventis U.S., LLC, 2011 U.S. Dist. LEXIS 128429 (D.N.J. Nov. 7, 2011); Eisai Inc. v. sanofi-aventis U.S., LLC, 2011 U.S. Dist. LEXIS 128430 (D.N.J. Nov. 7, 2011); Eisai Inc. v. sanofi-aventis U.S., LLC, 2011 U.S. Dist. LEXIS 128447 (D.N.J. Nov. 7, 2011); Pension Trust Fund for Operating Eng'r v. Mortgage Asset Securitization Trans., Inc., 2011 U.S. Dist. LEXIS 114090 (D.N.J. Sept. 29, 2011); Ass'n of N.J. Chiropractors v. Aetna, Inc., 2011 U.S. Dist. LEXIS 67718 (D.N.J. June 20, 2011); Ass'n of N.J. Chiropractors v. Aetna, Inc., 2011 U.S. Dist. LEXIS 67718 (D.N.J. June 17, 2011); TransWeb, LLC v. 3M Innovative Props. Co., 2011 U.S. Dist. LEXIS 59095 (D.N.J. June 1, 2011);Pieczenik v. Abbott Labs., 2011 U.S. Dist. LEXIS 29790 (D.N.J. Mar. 23, 2011); 1200 Grand Street Condo. Assoc. v. Tarragon Corp., 2011 Bankr. LEXIS 1001 (Bankr. D.N.J. Mar. 18, 2011); Aventis Pharm., Inc. v. Impax Labs., 2011 U.S. Dist. LEXIS 2858 (D.N.J. Jan. 11, 2011); Aventis Pharm., Inc. v. Impax Labs., 2011 U.S. Dist. LEXIS 3824 (D.N.J. Jan. 13, 2011); United States ex rel. Piacentile v. Sanofi Synthelabo, Inc., 2010 U.S. Dist. LEXIS 137895 (D.N.J. Dec. 31, 2010); Wyeth v. Orgenus Pharma, 2010 U.S. Dist. LEXIS 111004 (D.N.J. Oct. 19, 2010); 1200 Grand Street Condo. Assoc. v. Tarragon Corp., 2010 Bankr. LEXIS 3515 (Bankr. D.N.J. Oct. 1, 2010);Skolnick v. Tarragon Corp., 2010 Bankr. LEXIS 6290 (Bankr. D.N.J. Sept. 27, 2010); Eisai Inc. v. sanofi-aventis U.S., LLC, 2010 U.S. Dist. LEXIS 94460 (D.N.J. Sept. 20, 2010); In re Ins. Brokerage Antitrust Litig., 618 F.3d 300 (3d Cir. 2010); LLDV, L.P. v. Dinicola, 2010 U.S. Dist. LEXIS 82078 (D.N.J. Aug. 12, 2010); Eisai Inc. v. sanofi-aventis U.S., LLC, 2010 U.S. Dist. LEXIS 82291 (D.N.J. Aug. 10, 2010); In re N.J. Title Ins. Litig., 2010 U.S. Dist. LEXIS 67273 (D.N.J. July 6, 2010); Bauer v. Prudential Fin., Inc., 2010 U.S. Dist. LEXIS 64384 (D.N.J. June 29, 2010); Albany Molecular Research, Inc. v. Dr. Reddy's Labs., Ltd., 2010 U.S. Dist. LEXIS 59236 (D.N.J. June 14, 2010); Nelson v. Xacta 3000 Inc., 2010 U.S. Dist. LEXIS 47128 (D.N.J. May 12, 2010); Schering Corp. v. Glenmark Pharms., Inc. USA, 2010 U.S. Dist. LEXIS 38382 (D.N.J. Apr. 19, 2010); Fritzky v. Aetna Health, Inc., 2010 U.S. Dist. LEXIS 27730 (D.N.J. Mar. 24, 2010); In re Ins. Brokerage Antitrust Litig., 374 Fed. App'x 263 (3d Cir. 2010); In re Title Ins. Litig., 2009 U.S. Dist. LEXIS 80582 (D.N.J. Oct. 5, 2009); Novo Nordisk v. sanofi-aventis U.S. LLC, 2009 U.S. Dist. LEXIS 62657 (D.N.J. July 22, 2009); Schatz-Bernstein v. Keystone Food Prods., 2009 U.S. Dist. LEXIS 34700 (D.N.J. Apr. 17, 2009); Devito v. Aetna, Inc., 536 F. Supp. 2d 523 (D.N.J. 2008); Novo Nordisk v. sanofi-aventis U.S. LLC, 2008 U.S. Dist. LEXIS 12342 (D.N.J. Feb. 19, 2008); Appaloosa Inv., L.P.I. v. J.P. Morgan Sec., Inc., 398 N.J. Super. 52, 939 A.2d 257 (App. Div. 2008); Broadcom Corp. v. Qualcomm Inc., 501 F.3d 297 (3d Cir. 2007); Aventis Pharm., Inc. v. Barr Lab., Inc., 411 F. Supp. 2d 490 (D.N.J. 2006); In re Aventis Pharm., Inc., 372 F. Supp. 2d 430 (D.N.J. 2005); MOSAID Tech. Inc. v. Samsung Elec. Co., 362 F. Supp. 2d 526 (D.N.J. 2004); MOSAID Tech. Inc. v. Samsung Elec. Co., 348 F. Supp. 2d 595 (D.N.J. 2004); Di Giorgio Corp. v. Mendez and Co., 230 F. Supp. 2d 552 (D.N.J. 2002); Bio-Tech. Gen. Corp. v. Duramed Pharm., Inc., 174 F. Supp. 2d 229 (D.N.J. 2001); Biovail Corp. Int'l v. Hoechst Aktiengesellschaft, 49 F. Supp. 2d 750 (D.N.J. 1999); Eli Lilly and Co. v. Roussell Corp., 23 F. Supp. 2d 460 (D.N.J. 1998); Bryant v. N.J. Dept. of Transp., 1 F. Supp. 2d 426 (D.N.J. 1998); Bryant v. N.J. Dept. of Transp., 998 F. Supp. 438 (D.N.J. 1998).